Table 4

WBC PAH-DNA adduct levels for mothers and newborns by the CYP1A1 and GSTP1 genotypes analyzed in combinationa

Maternal WBC adduct levels Mean ± SD per 108 nucleotides (n)bNewborn WBC adduct levels Mean ± SD per 108 nucleotides (n)b
Group I: GSTP1 val/val + CYP1A1 MspI restriction site absent8.4 ± 11.4 (13)2.6 ± 2.3 (14)c,d,e,f
Group II: GSTP1 ile/val+ CYP1A1 MspI restriction site absent7.5 ± 11.5 (43)8.6 ± 10.0 (53)
Group III: GSTP1 ile/ile+ CYP1A1 MspI restriction site absent6.0 ± 8.5 (51)7.0 ± 8.6 (35)
Group IV: GSTP1 val/val + CYP1A1 MspI restriction site presentg1.0 ± 0.0 (2)9.3 ± 6.7 (2)
Group V: GSTP1 ile/val+ CYP1A1 MspI restriction site presentg4.6 ± 4.3 (10)9.8 ± 11.0 (17)
Group VI: GSTP1 ile/ile + CYP1A1 MspI restriction site presentg4.9 ± 4.6 (8)11.3 ± 16.4 (7)
  • a Maternal adduct levels are stratified by the mother’s genotype, and newborn adduct levels are stratified by the newborn’s genotype; all models are controlled for place of residence, cigarette smoking, dietary PAHs, use of coal stoves for residential heating, and home/occupational exposures. Associations of borderline significance (0.1 > P > 0.05) are reported but are considered statistically significant at P ≤ 0.05.

  • b Number of subjects.

  • c Newborn group I versus group VI (P = 0.04).

  • d Newborn group I versus group V (P = 0.02).

  • e Newborn group I versus group II (P = 0.04).

  • f Newborn group I versus group II–VI (P = 0.03).

  • g Homozygotes and heterozygotes combined.